Akademska digitalna zbirka SLovenije - logo

Search results

Basic search    Expert search   

Currently you are NOT authorised to access e-resources SI consortium. For full access, REGISTER.

1 2 3 4 5
hits: 197
1.
  • Trastuzumab Deruxtecan in P... Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
    Modi, Shanu; Saura, Cristina; Yamashita, Toshinari ... New England journal of medicine/˜The œNew England journal of medicine, 02/2020, Volume: 382, Issue: 7
    Journal Article
    Peer reviewed
    Open access

    In this single-group, phase 2 study, the use of trastuzumab deruxtecan resulted in a response in 60% of women with HER2-positive advanced breast cancer who had received a median of six previous lines ...
Full text
Available for: CMK, UL

PDF
2.
  • Molecular mechanisms of res... Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
    Pandey, Kamal; An, Hee‐Jung; Kim, Seung Ki ... International journal of cancer, 1 September 2019, Volume: 145, Issue: 5
    Journal Article
    Peer reviewed
    Open access

    Deregulation of the cyclin D‐CDK4/6‐INK4‐RB pathway leading to uncontrolled cell proliferation, is frequently observed in breast cancer. Currently, three selective CDK4/6 inhibitors have been FDA ...
Full text
Available for: BFBNIB, FZAB, GIS, IJS, KILJ, NLZOH, NUK, OILJ, SAZU, SBCE, SBMB, UL, UM, UPUK

PDF
3.
  • MONARCH 3: Abemaciclib As I... MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
    Goetz, Matthew P; Toi, Masakazu; Campone, Mario ... Journal of clinical oncology, 2017-Nov-10, 2017-11-10, 20171110, Volume: 35, Issue: 32
    Journal Article
    Peer reviewed

    Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)-positive, human ...
Full text
4.
  • Overall Survival with Riboc... Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
    Im, Seock-Ah; Lu, Yen-Shen; Bardia, Aditya ... New England journal of medicine/˜The œNew England journal of medicine, 07/2019, Volume: 381, Issue: 4
    Journal Article
    Peer reviewed
    Open access

    The addition of ribociclib to hormone therapy showed a greater benefit with regard to overall survival than hormone therapy alone in women with hormone-receptor–positive, human epidermal growth ...
Full text
Available for: CMK, UL

PDF
5.
  • Increased resting-state cer... Increased resting-state cerebellar-cortical connectivity in breast cancer survivors with cognitive complaints after chemotherapy
    Park, Hye Yoon; Lee, Hyeongrae; Sohn, Joohyuk ... Scientific reports, 06/2021, Volume: 11, Issue: 1
    Journal Article
    Peer reviewed
    Open access

    Abstract Cognitive complaints after chemotherapy are common in breast cancer patients, but the neural bases for these complaints remain unclear. This pilot study explored resting-state functional ...
Full text
Available for: IZUM, KILJ, NUK, PILJ, PNG, SAZU, UL, UM, UPUK

PDF
6.
  • Epithelial-to-mesenchymal t... Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer
    Hyun, Kyung-A; Koo, Gi-Bang; Han, Hyunju ... Oncotarget, 04/2016, Volume: 7, Issue: 17
    Journal Article
    Open access

    The dissemination of circulating tumor cells (CTCs) requires the Epithelial-to-Mesenchymal transition (EMT), in which cells lose their epithelial characteristics and acquire more mesenchymal-like ...
Full text
Available for: NUK, UL, UM, UPUK

PDF
7.
  • Continuous separation of br... Continuous separation of breast cancer cells from blood samples using multi-orifice flow fractionation (MOFF) and dielectrophoresis (DEP)
    Moon, Hui-Sung; Kwon, Kiho; Kim, Seung-Il ... Lab on a chip, 03/2011, Volume: 11, Issue: 6
    Journal Article
    Peer reviewed

    Circulating tumor cells (CTCs) are highly correlated with the invasive behavior of cancer, so their isolations and quantifications are important for biomedical applications such as cancer prognosis ...
Full text
Available for: IJS, KILJ, NUK, UL, UM
8.
  • Abemaciclib as initial ther... Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
    Johnston, Stephen; O'Shaughnessy, Joyce; Martin, Miguel ... NPJ breast cancer, 06/2021, Volume: 7, Issue: 1
    Journal Article
    Peer reviewed
    Open access

    In MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2- advanced breast cancer. We report data ...
Full text
Available for: NUK, UL, UM, UPUK

PDF
9.
  • Clinical implications of HE... Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
    Kim, Ji-Yeon; Park, Kyunghee; Im, Seock-Ah ... Breast cancer research and treatment, 12/2020, Volume: 184, Issue: 3
    Journal Article
    Peer reviewed

    Introduction We explored clinical implication of intrinsic molecular subtype in human epidermal growth factor receptor 2 (HER2) + metastatic breast cancer (BC) with pan-HER inhibitor from a phase II ...
Full text
Available for: EMUNI, FIS, FZAB, GEOZS, GIS, IJS, IMTLJ, KILJ, KISLJ, MFDPS, NLZOH, NUK, OBVAL, OILJ, PNG, SAZU, SBCE, SBJE, SBMB, SBNM, UKNU, UL, UM, UPUK, VKSCE, ZAGLJ
10.
  • Reply to A. Okeya et al Reply to A. Okeya et al
    Martín, Miguel; Sohn, Joohyuk Journal of clinical oncology, 07/2024
    Journal Article
    Peer reviewed
Full text
1 2 3 4 5
hits: 197

Load filters